Emerging therapies for multiple myeloma

ONCOLOGY

Volumn 23, Issue 5, 2009, Pages

  David, Dingli ^a   Rajkumar, S Viincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BORTEZOMIB; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GROWTH FACTOR; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; MM 009; MM 010; PAMIDRONIC ACID; PLACEBO; PLATINUM; PLERIXAFOR; PREDNISOLONE; PREDNISONE; PROTEASOME INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CELL LABELING; CLINICAL ASSESSMENT; CLINICAL TRIAL; CYTOGENETICS; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LOW DRUG DOSE; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGNOSIS; REVIEW; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

EID: 70249106775     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520, 2008.
2. Bergsagel PL, Kuehl WM: Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23:6333-6338, 2005. (Pubitemid 46218843)
3. Kuehl WM, Bergsagel PL: Multiple myeloma: Evolving genetic events and host interactions. Nat Rev 2:175-187, 2002.
4. Dispenzieri A, Rajkumar SV, Gertz MA, et al: Treatment of newly diagnosed multiple myeloma based on mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus statement. Mayo Clin Proc 82:323-341, 2007. (Pubitemid 46348934)
5. Stewart AK, Bergsagel PL, Greipp PR, et al: A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 21:529-534, 2007.
6. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999.
7. DAmato RJ, Lentzsch S, Anderson KC, et al: Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol 28:597-601, 2001. (Pubitemid 33134418)
8. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003. (Pubitemid 36741588)
9. Shaughnessy J, Barlogie B: Chromosome 13 deletion in myeloma. Curr Top Microbiol Immunol 246:199-203, 1999.
10. Fonseca R, Barlogie B, Bataille R, et al: Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 64:1546-1558, 2004. (Pubitemid 38235629)
11. Barlogie B, Jagannath S, Desikan KR, et al: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55-65, 1999. (Pubitemid 29019388)
12. Dingli D, Nowakowski GS, Dispenzieri A, et al: Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: A simple risk stratification system. Blood 107:3384-3388, 2006.
13. Harousseau JL: Induction therapy in multiple myeloma. ASH Education Book 2008, pp 306-312. Hematology/the Education Program of the American Society of Hematology Education Program Book, 2008.
14. Dingli D, Nowakowski GS, Dispenzieri A, et al: Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 6:384-388, 2006.
15. Tricot GJ: What is the significance of molecular remission in multiple myeloma? Clin Adv Hematol Oncol 5:91-95, 2007.
16. Dingli D, Pacheco JM, Nowakowski GS, et al: Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 25:4933-4937, 2007. (Pubitemid 350220425)
17. Bergsagel PL: A kinder, gentler way: Control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy. Leukemia 22:673-675, 2008.
18. Barlogie B, van Rhee F, Shaughnessy JD Jr, et al: Making progress in treating multiple myeloma with total therapies: Issue of complete remission and more. Leukemia 22:1633-1636, 2008.
19. Cavo M, Zamagni E, Tosi P, et al: Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106:35-39, 2005. (Pubitemid 40967171)
20. Rajkumar SV, Rosinol L, Hussein M, et al: Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26:2171-2177, 2008.
21. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al: Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 93:124-127, 2008. (Pubitemid 351156161)
22. Rajkumar SV, Blood E, Vesole D, et al: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431-436, 2006. (Pubitemid 46630462)
23. Palumbo A, Rajkumar SV, Dimopoulos MA, et al: Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414-423, 2008. (Pubitemid 351255436)
24. Rajkumar SV, Hayman SR, Lacy MQ, et al: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050-4053, 2005.
25. Barlogie B, Anaissie E, van Rhee F, et al: Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of Total Therapy 3. Br J Haematol 138:176-185, 2007. (Pubitemid 46978271)
26. Rajkumar S, Jacobus S, Collander N, et al: Randomized trial of lenalidomide plus hig-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome (abstract 8504). J Clin Oncol 26(15S):455s, 2008.
27. Kumar S, Dispenzieri A, Lacy MQ, et al: Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21:2035-2042, 2007. (Pubitemid 47299979)
28. Mazumder A, Kaufman J, Niesvizky R, et al: Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients (letter). Leukemia 22:1280-1282 (incl author reply), 2008. (Pubitemid 351833803)
29. Paripati H, Stewart AK, Cabou S, et al: Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 22:1282-1284, 2008. (Pubitemid 351833805)
30. Mark T, Stern J, Furst JR, et al: Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 14:795-798, 2008. (Pubitemid 351773154)
31. Mitsiades N, Mitsiades CS, Poulaki V, et al: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99:14374-14379, 2002. (Pubitemid 35257679)
32. Mitsiades N, Mitsiades CS, Poulaki V, et al: Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications. Blood 99:4079-4086, 2002. (Pubitemid 35332050)
33. Harousseau JL, Attal M, Leleu X, et al: Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study. Haematologica 91:1498-1505, 2006. (Pubitemid 44736116)
34. Rosinol L, Oriol A, Mateos MV, et al: Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: Efficacy and clinical implications of tumor response kinetics. J Clin Oncol 25:4452-4458, 2007. (Pubitemid 350013852)
35. Harousseau JL, Mathiot C, Attal M, et al: Velcade/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): Updated results of the IFM 2005/01 trial (abstract 450). Blood 110, 2007.
36. Mitsiades N, Mitsiades CS, Richardson PG, et al: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 101:2377-2380, 2003. (Pubitemid 36302084)
37. Wang M, Giralt S, Delasalle K, et al: Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 12:235-239, 2007. (Pubitemid 46930250)
38. Cavo M, Patriarca F, Tocchetti M, et al: Bortezomib (Velcade)- thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM) (abstract 73). Blood 110, 2007.
39. Oakervee HE, Popat R, Curry N, et al: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129:755-762, 2005. (Pubitemid 40904525)
40. Richardson P, Jagannath S, Raje N, et al: Lenalidomide, bortezomib and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): Preliminary results of a phase 1/2 study (abstract 187). Blood 110, 2007.
41. Reeder CB, Reece DE, Kukreti V, et al: Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial. Leukemia Feb 19, 2009 (epub ahead of print).
42. Kumar SK, Dingli D, Dispenzieri A, et al: Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous sct. Bone Marrow Transplant 41:1013-1019, 2008. (Pubitemid 352034176)
43. Dingli D, Pacheco JM, Dispenzieri A, et al: Serum m-spike and transplant outcome in patients with multiple myeloma. Cancer Sci 98:1035-1040, 2007. (Pubitemid 46865388)
44. Dingli D, Pacheco JM, Dispenzieri A, et al: In vivo and in silico studies on single versus multiple transplants for multiple myeloma. Cancer Sci 98:734-739, 2007.
45. Jagannath S, Richardson PG, Sonneveld P, et al: Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21:151-157, 2007. (Pubitemid 44921846)
46. McElwain TJ, Powles RL: High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2:822-824, 1983.
47. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91-97, 1996. (Pubitemid 26240110)
48. Barlogie B: Hemopoietic stem cell transplant for multiple myeloma (MM). Leukemia 7:1095, 1993.
49. Barlogie B, Tricot G, Anaissie E, et al: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021-1030, 2006. (Pubitemid 43357806)
50. Barlogie B, Pineda-Roman M, van Rhee F, et al: Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112:3115-3121, 2008.
51. Morgan GJ, Jackson GH, Davies FE, et al: Maintenance thalidomide may improve progression free but not overall survival; results from the Myeloma IX Maintenance Randomisation (abstract 656). Blood 112, 2008.
52. Attal M, Harousseau JL, Leyvraz S, et al: Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289-3294, 2006. (Pubitemid 44776865)
53. Abdelkefi A, Ladeb S, Torjman L, et al: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: Results of a multicenter randomized clinical trial. Blood 111:1805-1810, 2008.
54. Spencer A, Prince M, Roberts AW, et al: First analysis of the Australasian Leukemia and Lymphoma Group (ALLG) trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6) (abstract 58). Blood 108, 2006.
55. Schiller GJ, Liao M, Sohn JP, et al: Phase I/II trial of bortezomib maintenance following autologous peripheral blood progenitor cell transplantation as treatment for intermediate- and advanced-stage multiple myeloma (abstract 176). Biol Blood Marrow Transplant 14, 2008.
56. Gertz MA, Ansell SM, Dingli D, et al: Autologous stem cell transplant in 716 patients with multiple myeloma: Low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 83:1131-1138, 2008.
57. Ludwig H, Hajek R, Tothova E, et al: Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood Oct 27, 2008 (epub ahead of print).
58. Palumbo A, Bringhen S, Caravita T, et al: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 367:825-831, 2006. (Pubitemid 43363369)
59. Palumbo A, Bringhen S, Liberati AM, et al: Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized controlled trial. Blood 112:3107-3114, 2008.
60. Facon T, Mary JY, Hulin C, et al: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 370:1209-1218, 2007. (Pubitemid 47516593)
61. Hulin C, Facon T, Rodon P, et al: Melphala-prednisone-thalidomide (mp-t) demonstrates a significant survival advantage in elderly patients > 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double blind, placebo-controlled tial, IFM 01/01 (abstract 75). Blood 110, 2007.
62. Palumbo A, Falco P, Corradini P, et al: Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMAItalian Multiple Myeloma Network. J Clin Oncol 25:4459-4465, 2007. (Pubitemid 350063804)
63. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008.
64. Harousseau JL, Palumbo A, Richardson P, et al: Superior outcomes associated with complete response: Analysis of the phase III VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone (abstract 2778). Blood 112, 2008.
65. Palumbo A, Avonto I, Patriarca F, et al: Bortezomib, pegylated-piposoma- doxorubicin and dexamethasone followed by melphalan 100mg/m2 in elderly newly diagnosed patients: An interim analysis (abstract 448). Blood 110, 2007.
66. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase i trial of the proteasome inhibitor ps-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002. (Pubitemid 35334752)
67. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005. (Pubitemid 41007864)
68. Richardson PG, Sonneveld P, Schuster M, et al: Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the apex trial. Blood 110:3557-3560, 2007. (Pubitemid 350159621)
69. Weber DM, Chen C, Niesvizky R, et al: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133-2142, 2007. (Pubitemid 350146108)
70. Dimopoulos M, Spencer A, Attal M, et al: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123-2132, 2007. (Pubitemid 350146107)
71. Wang M, Dimopoulos MA, Chen C, et al: Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112:4445-4451, 2008.
72. Morgan GJ, Schey SA, Wu P, et al: Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 137:268-269, 2007. (Pubitemid 46537629)
73. Baz R, Walker E, Karam MA, et al: Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: Safety and efficacy. Ann Oncol 17:1766-1771, 2006. (Pubitemid 44884050)